Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy has been initiated.
February 19, 2019: Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy
February 14, 2019: Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors
February 6, 2019: Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team